Fig. 3From: Galcanezumab effects on incidence of headache after occurrence of triggers, premonitory symptoms, and aura in responders, non-responders, super-responders, and super non-respondersIdentification of galcanezumab non-responder. Note that the percentage of monthly migraine days (MMD) decreased by < 50% during the treatment period (from 80% before treatment to 54.6% during the 3 months of treatment)Back to article page